Видео ютуба по тегу Medicines: Vemurafenib

Combination therapies with vemurafenib in BRAF v600E–mutant cancers
Combination therapies with vemurafenib in BRAF v600E–mutant cancers
Vemurafenib and cobimetinib in patients with BRAF-mutated melanoma
Vemurafenib and cobimetinib in patients with BRAF-mutated melanoma
Vemurafenib in patients with BRAF600 mutation–positive metastatic melanoma
Vemurafenib in patients with BRAF600 mutation–positive metastatic melanoma
Study of Vemurafenib Combined With a MEK Inhibitor
Study of Vemurafenib Combined With a MEK Inhibitor
Dr. Omid Hamid on Vemurafenib and Atezolizumab in Melanoma
Dr. Omid Hamid on Vemurafenib and Atezolizumab in Melanoma
Expert Discusses the Safety of Vemurafenib
Expert Discusses the Safety of Vemurafenib
Melanoma Brain Metastases and Vemurafenib: Need for Further Investigation
Melanoma Brain Metastases and Vemurafenib: Need for Further Investigation
BRAF Targeted Therapy - Melanoma Education Symposium, Peter Boasberg MD
BRAF Targeted Therapy - Melanoma Education Symposium, Peter Boasberg MD
Vemurafenib for high risk melanoma patients
Vemurafenib for high risk melanoma patients
Targeted Therapy: BRAF and Beyond
Targeted Therapy: BRAF and Beyond
Dr. Chapman Describes the Vemurafenib Clinical Trial
Dr. Chapman Describes the Vemurafenib Clinical Trial
Resistance in BRAF and KRAS Mutant Cancers - by Ryan Corcoran, MD, PhD
Resistance in BRAF and KRAS Mutant Cancers - by Ryan Corcoran, MD, PhD
Advanced Melanoma
Advanced Melanoma
Dr. Jae Park Describes a Trial Investigating Vemurafenib for the Treatment of Hairy Cell Leukemia
Dr. Jae Park Describes a Trial Investigating Vemurafenib for the Treatment of Hairy Cell Leukemia
Keynote Lecture 4: The BRAF pathway in CRC?
Keynote Lecture 4: The BRAF pathway in CRC?
IMspire 150: Atezolizumab, cobimetinib and vemurafenib in untreated patients with BRAFV600 mutat...
IMspire 150: Atezolizumab, cobimetinib and vemurafenib in untreated patients with BRAFV600 mutat...
Phase II trial of obinutuzumab, alone and combined with vemurafenib, in R/R hairy cell leukemia
Phase II trial of obinutuzumab, alone and combined with vemurafenib, in R/R hairy cell leukemia
Zelboraf (Vemurafenib)- metastatic melanoma
Zelboraf (Vemurafenib)- metastatic melanoma